Chronic Hepatitis b
Conditions
Keywords
prevalence, vaccine coverage, risk factors, morbidity, mortality, quality of life, economic vulnerability, food security, treatment needs, decentralized care, health costs, caregivers training
Brief summary
This study aims at estimating the prevalence of chronic hepatitis B virus (HBV) infection in rural Senegal (area of Niakhar) and at evaluating the associated burden in terms of both health-related and socio-economic consequences.
Detailed description
The prevalence of chronic HBV infection in Senegal is among the highest worldwide (10% to 17%) but available prevalence estimates relie on studies conducted in specific subgroups (such as military, pregnant women or blood donors). The prevalence of HBV chronic infection remains undocumented in the general population of Senegal, and its health-related and socio-economic consequences need to be estimated. This research is based on a cross-sectional survey conducted in the general population with collection of biological, socio-behavioral and economic data at two levels (at the participants' home and in healthcare centers) in the area of Niakhar (located at 135 kms at the East of Dakar). The research includes three phases as follows: (i) Preliminary phase: information and communication about the research within the community, training of stakeholders and pilot survey (ii) Collection of data in the general population (iii) Communication of results on HBV status to participants and collection of additional data among HBV chronic individuals
Interventions
DIAGNOSTIC_TESTHBV testing with dried blood spots (DBS) technique
Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
Sponsors
Institute of Research for Development, France
ANRS, Emerging Infectious Diseases
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
6 Months to No maximum
Healthy volunteers
Yes
Inclusion criteria
(i) Living in a household of the research zone (individuals living within participating households for at least 6 months, even non permanently: seasonal workers or individuals studying outside the Niakhar zone) (ii) Being aged of at least 6 months (iii) Giving informed consent to participate in the research
Exclusion criteria
(i) Being an adult unable to sign informed consent (ii) Being a child whose parents or legal guardian is not present in the household at the time of the survey
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence of chronic HBV infection | At baseline | HBs Ag positivity with a positive anti-HBc antibody and a negative anti-HBs antibody |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| HBV vaccine coverage (in children born after 2004, year of the introduction of the vaccine in the national program) | At baseline | HBs Ag negativity with a negative anti-HBc antibody and positive anti-HBs antibody |
| HBV vaccine efficacy (in children born after 2004, year of the introduction of the vaccine in the national program) | At baseline | Titration of anti-HBs antibody \> 10 UI/l among vaccinated participants |
| Mortality associated with chronic HBV infection in the Niakhar area | 6 months | Rate of deaths in the area |
| Morbidity associated with chronic HBV infection in the Niakhar area | 6 months | Rate of HBV-related hospitalizations/healthcare use in the area |
| Prevalence of chronic HBV infection in age classes '0-15 years; 15-35 years, more than 35 years), and in women of childbearing age | At baseline | HBs Ag positivity |
| HBV treatment needs in the Niakhar area and in the country | At baseline | Number of HBV-chronic individuals eligible to HBV treatment (according to WHO criteria) in the area, extrapolation to the needs in other areas of Senegal |
| Number of quality-adjusted life years(QALYs) lost in the absence of HBV treatment | 6 months | Use of Markov simulation models |
| Number of QALYs gained with different scenario of access to HBV treatment | 6 months | Use of Markov simulation models |
| Total cost | 6 months | Use of Markov simulation models (with different scenarii of change in access to HBV treatment and amount of the financial contributions of populations, government and international programs) |
| Quality of life and living conditions of HBV-infected individuals and of their households | 6 months | Comparison of quality of life scores and socio-economic characteristics between HBV-concerned and HBV not-concerned households |
Countries
Senegal
Outcome results
None listed